RxDoctor Payments Data

Shabana Dewani, MD

Hematology & Oncology · Columbus, OHNPI 1306928817

Payments from drug & device makers

$7,175in general payments, 2019–2025

Across 40 payments — averaging $179.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Merck$3K
  • Genentech USA, Inc.$171
  • Endomagnetics Ltd$152
  • Mckesson Specialty Care Distribution, LLC$101
  • Amgen$99
  • plus $122 from 4 others

What the payments were for

  • Consulting fees$3,68585%
  • Food & beverage$44310%
  • Education$2015%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$3,685
Merck29$2,846
Genentech USA, Inc.2$171
Endomagnetics Ltd1$152
Mckesson Specialty Care Distribution, LLC2$101
Amgen1$99
Novartis1$73
Johnson & Johnson1$21
E.r. Squibb & Sons, L.L.C.1$16
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,175 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,115,864
Medicare patients
349
Services billed
107,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate24$418,506
VerzenioAbemaciclib18$263,132
InlytaAxitinib11$227,141
BrukinsaZanubrutinib12$184,408
ImbruvicaIbrutinib12$133,975
TukysaTucatinib12$106,447
Lenalidomide13$77,793
EliquisApixaban45$25,490
Abiraterone Acetate11$19,373
Anastrozole313$5,108
Exemestane45$3,452
Letrozole164$2,444
Hydroxyurea26$711
Duloxetine Hcl13$617
Tamoxifen Citrate23$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$73$418,50624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →